Intervention Review

You have free access to this content

Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction

  1. Maria Makrides1,*,
  2. Lelia Duley2,
  3. Sjurdur F Olsen3

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 19 JUL 2006

Assessed as up-to-date: 18 APR 2006

DOI: 10.1002/14651858.CD003402.pub2


How to Cite

Makrides M, Duley L, Olsen SF. Marine oil, and other prostaglandin precursor, supplementation for pregnancy uncomplicated by pre-eclampsia or intrauterine growth restriction. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD003402. DOI: 10.1002/14651858.CD003402.pub2.

Author Information

  1. 1

    Women's and Children's Health Research Institute, Child Nutrition Research Centre, North Adelaide, SA, Australia

  2. 2

    University of Nottingham, Nottingham Clinical Trials Unit, Nottingham, UK

  3. 3

    Institute of Public Health, Aarhus C, Denmark

*Maria Makrides, Child Nutrition Research Centre, Women's and Children's Health Research Institute, Women's and Children's Hospital, 72 King William Road, North Adelaide, SA, 5006, Australia. maria.makrides@health.sa.gov.au.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 19 JUL 2006

SEARCH

[Analysis 1.1]
Analysis 1.1. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 1 High blood pressure (without proteinuria).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 2 Pre-eclampsia (hypertension with proteinuria).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 3 Eclampsia or other serious maternal morbidity.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 4 Maternal death.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 5 Maternal antepartum hospitalisation.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 6 Mother's length stay in hospital (days).
[Analysis 1.7]
Analysis 1.7. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 7 Antepartum vaginal bleeding.
[Analysis 1.8]
Analysis 1.8. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 8 Maternal anaemia.
[Analysis 1.9]
Analysis 1.9. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 9 Maternal side-effects.
[Analysis 1.10]
Analysis 1.10. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 10 Caesarean section.
[Analysis 1.12]
Analysis 1.12. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 12 Blood loss at delivery (mls).
[Analysis 1.13]
Analysis 1.13. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 13 Vaginal blood loss after delivery.
[Analysis 1.14]
Analysis 1.14. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 14 Miscarriage (< 24 weeks).
[Analysis 1.15]
Analysis 1.15. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 15 Stillbirth (= or > 24 weeks).
[Analysis 1.16]
Analysis 1.16. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 16 Neonatal death.
[Analysis 1.17]
Analysis 1.17. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 17 Length of gestation (days).
[Analysis 1.18]
Analysis 1.18. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 18 Preterm birth (< 37 weeks).
[Analysis 1.19]
Analysis 1.19. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 19 Early preterm birth (< 34 weeks).
[Analysis 1.20]
Analysis 1.20. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 20 Prolonged gestation (> 42 weeks).
[Analysis 1.21]
Analysis 1.21. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 21 Small-for-gestational age.
[Analysis 1.22]
Analysis 1.22. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 22 Low birthweight (< 2500 g).
[Analysis 1.24]
Analysis 1.24. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 24 Birthweight (gm).
[Analysis 1.25]
Analysis 1.25. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 25 Birth length (cm).
[Analysis 1.26]
Analysis 1.26. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 26 Congenital malformation.
[Analysis 1.27]
Analysis 1.27. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 27 Baby admitted to neonatal care.
[Analysis 1.28]
Analysis 1.28. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 28 Baby's length of stay in hospital (days).
[Analysis 1.29]
Analysis 1.29. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 29 Neonatal morbidity - bleeding disorders (eg IVH).
[Analysis 1.30]
Analysis 1.30. Comparison 1 Prostagladin precursor supplementation versus none or placebo - all women, Outcome 30 Neonatal morbidity - non-bleeding disorders (eg RDS).
[Analysis 2.1]
Analysis 2.1. Comparison 2 Prostaglandin precursor supplementation versus none or placebo - subgroups by gestation at trial entry, Outcome 1 Pre-eclampsia (hypertension with proteinuria).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Prostaglandin precursor supplementation versus none or placebo - subgroups by gestation at trial entry, Outcome 2 Length of gestation (days).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Prostaglandin precursor supplementation versus none or placebo - subgroups by gestation at trial entry, Outcome 3 Preterm birth (< 37 weeks).
[Analysis 2.4]
Analysis 2.4. Comparison 2 Prostaglandin precursor supplementation versus none or placebo - subgroups by gestation at trial entry, Outcome 4 Prolonged gestation (> 42 weeks).
[Analysis 2.5]
Analysis 2.5. Comparison 2 Prostaglandin precursor supplementation versus none or placebo - subgroups by gestation at trial entry, Outcome 5 Birthweight (gm).
[Analysis 2.6]
Analysis 2.6. Comparison 2 Prostaglandin precursor supplementation versus none or placebo - subgroups by gestation at trial entry, Outcome 6 Low birthweight (< 2500 g).
[Analysis 2.7]
Analysis 2.7. Comparison 2 Prostaglandin precursor supplementation versus none or placebo - subgroups by gestation at trial entry, Outcome 7 Small-for-gestational age.
[Analysis 2.8]
Analysis 2.8. Comparison 2 Prostaglandin precursor supplementation versus none or placebo - subgroups by gestation at trial entry, Outcome 8 Stillbirth (= or > 24 weeks).
[Analysis 2.9]
Analysis 2.9. Comparison 2 Prostaglandin precursor supplementation versus none or placebo - subgroups by gestation at trial entry, Outcome 9 Neonatal death.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Prostaglandin precursor supplementation versus none or placebo - subgroups by singleton or multiple pregnancy, Outcome 1 Pre-eclampsia (hypertension with proteinuria).
[Analysis 3.2]
Analysis 3.2. Comparison 3 Prostaglandin precursor supplementation versus none or placebo - subgroups by singleton or multiple pregnancy, Outcome 2 Length of gestation (days).
[Analysis 3.3]
Analysis 3.3. Comparison 3 Prostaglandin precursor supplementation versus none or placebo - subgroups by singleton or multiple pregnancy, Outcome 3 Preterm birth (< 37 weeks).
[Analysis 3.4]
Analysis 3.4. Comparison 3 Prostaglandin precursor supplementation versus none or placebo - subgroups by singleton or multiple pregnancy, Outcome 4 Prolonged gestation (> 42 weeks).
[Analysis 3.5]
Analysis 3.5. Comparison 3 Prostaglandin precursor supplementation versus none or placebo - subgroups by singleton or multiple pregnancy, Outcome 5 Birthweight (gm).
[Analysis 3.6]
Analysis 3.6. Comparison 3 Prostaglandin precursor supplementation versus none or placebo - subgroups by singleton or multiple pregnancy, Outcome 6 Birthweight < 2500 g.
[Analysis 3.7]
Analysis 3.7. Comparison 3 Prostaglandin precursor supplementation versus none or placebo - subgroups by singleton or multiple pregnancy, Outcome 7 Small-for-gestational age.
[Analysis 3.8]
Analysis 3.8. Comparison 3 Prostaglandin precursor supplementation versus none or placebo - subgroups by singleton or multiple pregnancy, Outcome 8 Stillbirth (= or > 24 weeks).
[Analysis 3.9]
Analysis 3.9. Comparison 3 Prostaglandin precursor supplementation versus none or placebo - subgroups by singleton or multiple pregnancy, Outcome 9 Neonatal death.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Prostaglandin precursor supplementation versus none or placebo in singleton pregnancy - subgroups by risk, Outcome 1 Pre-eclampsia (hypertension with proteinuria).
[Analysis 4.2]
Analysis 4.2. Comparison 4 Prostaglandin precursor supplementation versus none or placebo in singleton pregnancy - subgroups by risk, Outcome 2 Length of gestation (days).
[Analysis 4.3]
Analysis 4.3. Comparison 4 Prostaglandin precursor supplementation versus none or placebo in singleton pregnancy - subgroups by risk, Outcome 3 Preterm birth (< 37 weeks).
[Analysis 4.4]
Analysis 4.4. Comparison 4 Prostaglandin precursor supplementation versus none or placebo in singleton pregnancy - subgroups by risk, Outcome 4 Prolonged gestation (> 42 weeks).
[Analysis 4.5]
Analysis 4.5. Comparison 4 Prostaglandin precursor supplementation versus none or placebo in singleton pregnancy - subgroups by risk, Outcome 5 Birthweight (gm).
[Analysis 4.6]
Analysis 4.6. Comparison 4 Prostaglandin precursor supplementation versus none or placebo in singleton pregnancy - subgroups by risk, Outcome 6 Low birthweight (< 2500 g).
[Analysis 4.7]
Analysis 4.7. Comparison 4 Prostaglandin precursor supplementation versus none or placebo in singleton pregnancy - subgroups by risk, Outcome 7 Small-for-gestational age.
[Analysis 4.8]
Analysis 4.8. Comparison 4 Prostaglandin precursor supplementation versus none or placebo in singleton pregnancy - subgroups by risk, Outcome 8 Stillbirth (= or > 24 weeks).
[Analysis 4.9]
Analysis 4.9. Comparison 4 Prostaglandin precursor supplementation versus none or placebo in singleton pregnancy - subgroups by risk, Outcome 9 Neonatal death.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Prostaglandin precursor supplementation versus placebo - subgroups by type of supplement, Outcome 1 Pre-eclampsia (hypertension with proteinuria).
[Analysis 5.2]
Analysis 5.2. Comparison 5 Prostaglandin precursor supplementation versus placebo - subgroups by type of supplement, Outcome 2 Length of gestation (days).
[Analysis 5.3]
Analysis 5.3. Comparison 5 Prostaglandin precursor supplementation versus placebo - subgroups by type of supplement, Outcome 3 Preterm birth (< 37 weeks).
[Analysis 5.4]
Analysis 5.4. Comparison 5 Prostaglandin precursor supplementation versus placebo - subgroups by type of supplement, Outcome 4 Prolonged gestation (> 42 weeks).
[Analysis 5.5]
Analysis 5.5. Comparison 5 Prostaglandin precursor supplementation versus placebo - subgroups by type of supplement, Outcome 5 Birthweight (gm).
[Analysis 5.6]
Analysis 5.6. Comparison 5 Prostaglandin precursor supplementation versus placebo - subgroups by type of supplement, Outcome 6 Low birthweight (< 2500 g).
[Analysis 5.7]
Analysis 5.7. Comparison 5 Prostaglandin precursor supplementation versus placebo - subgroups by type of supplement, Outcome 7 Small-for-gestational age.
[Analysis 5.8]
Analysis 5.8. Comparison 5 Prostaglandin precursor supplementation versus placebo - subgroups by type of supplement, Outcome 8 Stillbirth (= or > 24 weeks).
[Analysis 5.9]
Analysis 5.9. Comparison 5 Prostaglandin precursor supplementation versus placebo - subgroups by type of supplement, Outcome 9 Neonatal death.